Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3427 in Healthy Volunteers and Heart Failure Patients
NCT04630067Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD3427 in heart failure (HF) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants Experiencing Adverse Events and Serious Adverse Events. Started Nov 2020; status: completed.
02
Drugs
AZD3427
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04630067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630067.